GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
The month ahead: April’s upcoming events
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
Blenrep surprises again
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.
The complex web of PARP inhibitor development
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
